The emerging role of PARP inhibitors in prostate cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In prostate cancer , there has recently been an emerging interest in mutations in genes belonging to the homologous recombination repair (HRR) pathway and in the inhibition of poly (ADP-ribose) polymerase (PARP) proteins.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Expert Rev Anticancer Ther

Title: Expert review of anticancer therapy

Publisher: Informa UK Limited

ISSN (Electronic): 1744-8328

ISSN (Print): 1473-7140

Publication date (Electronic): August 2020

Volume: 20

Issue: 8

Affiliations

[1 ] Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori , Milan, Italy.

[2 ] Department of Oncology and Hemato-Oncology, University of Milan , Milan, Italy.

[3 ] Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale Dei Tumori , Milano, Italy.

[4 ] Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Dei Tumori , Milano, Italy.

[5 ] Department of Medical Oncology, Campus Bio-Medico University of Rome , Rome, Italy.

Article

DOI: 10.1080/14737140.2020.1797497

PubMed ID: 32758032

SO-VID: fef51f25-d3d9-4779-8d81-07a614197fc3

History

Keywords: BRCA-1,BRCA-2,HRR genes,PARPi,metastatic castration resistance prostatic cancer,niraparib,olaparib,rucaparib,talazoparib,veliparib

Data availability:

Keywords: BRCA-1, BRCA-2, HRR genes, PARPi, metastatic castration resistance prostatic cancer, niraparib, olaparib, rucaparib, talazoparib, veliparib

The emerging role of PARP inhibitors in prostate cancer.

Read this article at

Abstract

Related collections

Cancer Metabolism

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Cited by 3